Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.

Cea M, Cagnetta A, Patrone F, Nencioni A, Gobbi M, Anderson KC.

Autophagy. 2013 Mar;9(3):410-2.

2.

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2012 Oct 25;120(17):3519-29. doi: 10.1182/blood-2012-03-416776. Epub 2012 Sep 5.

4.

NAD depletion by FK866 induces autophagy.

Billington RA, Genazzani AA, Travelli C, Condorelli F.

Autophagy. 2008 Apr;4(3):385-7. Epub 2008 Jan 23.

PMID:
18227641
5.

Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.

Yang P, Zhang L, Shi QJ, Lu YB, Wu M, Wei EQ, Zhang WP.

Pharmazie. 2015 Oct;70(10):650-5.

PMID:
26601421
6.

Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.

Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nüssler V, Hasmann M.

Eur J Med Res. 2006 Aug 30;11(8):313-21.

PMID:
17052966
7.

FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.

Schuster S, Penke M, Gorski T, Gebhardt R, Weiss TS, Kiess W, Garten A.

Biochem Biophys Res Commun. 2015 Mar 6;458(2):334-40. doi: 10.1016/j.bbrc.2015.01.111. Epub 2015 Feb 3.

PMID:
25656579
8.

The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.

Nahimana A, Aubry D, Breton CS, Majjigapu SR, Sordat B, Vogel P, Duchosal MA.

Leuk Lymphoma. 2014 Sep;55(9):2141-50. doi: 10.3109/10428194.2013.869325. Epub 2014 Jan 24.

PMID:
24283753
9.

A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.

Song TY, Yeh SL, Hu ML, Chen MY, Yang NC.

Biogerontology. 2015 Dec;16(6):789-800. doi: 10.1007/s10522-015-9605-9. Epub 2015 Sep 2.

PMID:
26330291
10.

On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.

Gehrke I, Bouchard ED, Beiggi S, Poeppl AG, Johnston JB, Gibson SB, Banerji V.

Clin Cancer Res. 2014 Sep 15;20(18):4861-72. doi: 10.1158/1078-0432.CCR-14-0624. Epub 2014 Aug 29.

11.

EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.

Zucal C, D'Agostino VG, Casini A, Mantelli B, Thongon N, Soncini D, Caffa I, Cea M, Ballestrero A, Quattrone A, Indraccolo S, Nencioni A, Provenzani A.

BMC Cancer. 2015 Nov 5;15:855. doi: 10.1186/s12885-015-1845-1.

12.

Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.

Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ, Yagi T, Felding-Habermann B.

J Clin Invest. 2013 Mar;123(3):1068-81. doi: 10.1172/JCI64264. Epub 2013 Feb 15.

13.

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.

Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA.

Cell Death Dis. 2015 Jan 15;6:e1599. doi: 10.1038/cddis.2014.564.

14.

Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.

Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, Hasmann M, Saltz LB, Koutcher JA.

Clin Cancer Res. 2005 May 1;11(9):3503-13.

15.

FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes.

Oyarzún AP, Westermeier F, Pennanen C, López-Crisosto C, Parra V, Sotomayor-Flores C, Sánchez G, Pedrozo Z, Troncoso R, Lavandero S.

Biochem Pharmacol. 2015 Nov 1;98(1):92-101. doi: 10.1016/j.bcp.2015.08.097. Epub 2015 Aug 20.

PMID:
26297909
16.

Control of autophagic cell death by caspase-10 in multiple myeloma.

Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM.

Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub 2013 Mar 28.

17.

Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.

Thakur BK, Dittrich T, Chandra P, Becker A, Kuehnau W, Klusmann JH, Reinhardt D, Welte K.

Int J Cancer. 2013 Feb 15;132(4):766-74. doi: 10.1002/ijc.27726. Epub 2012 Aug 12.

18.

Anticancer agent CHS-828 inhibits cellular synthesis of NAD.

Olesen UH, Christensen MK, Björkling F, Jäättelä M, Jensen PB, Sehested M, Nielsen SJ.

Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. doi: 10.1016/j.bbrc.2008.01.019. Epub 2008 Jan 15.

PMID:
18201551
19.

Reovirus modulates autophagy during oncolysis of multiple myeloma.

Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, Neri P, Pho M, Stewart D, Mansoor A, Morris DG.

Autophagy. 2013 Mar;9(3):413-4. doi: 10.4161/auto.22867. Epub 2013 Jan 15.

20.

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.

Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjørnelund J, Dawson KM, Dupuis M, Duchosal MA.

Blood. 2009 Apr 2;113(14):3276-86. doi: 10.1182/blood-2008-08-173369. Epub 2009 Feb 5.

Supplemental Content

Support Center